Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanotax is a nanoparticle formulation of the taxane chemotherapy agent paclitaxel, developed by CritiTech using its proprietary supercritical fluid precipitation technology. Unlike conventional paclitaxel formulations such as Taxol, which require surfactants like Cremophor EL and ethanol for solubility, Nanotax consists of pure paclitaxel particles in the nanometer range. This formulation is specifically designed for intraperitoneal (IP) administration to treat peritoneal neoplasms, including those originating from ovarian, colorectal, and gastric cancers. By delivering the drug directly into the peritoneal cavity, Nanotax aims to achieve high local concentrations of the active agent while minimizing systemic exposure and associated toxicities, such as hypersensitivity reactions and peripheral neuropathy, thereby potentially improving the therapeutic index for patients with refractory peritoneal malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nanotax.